title: Effects of sCD23 on proliferation of leukemic cells from a patient with chronic myelogenous leukemia during blast crisis.
abstract: The present study has attempted to further delineate the growth factor requirements of peripheral blasts of a patient with CML in acute phase. Phenotypic analysis of leukemic blasts from this patient before culture has shown a homogenous population of CD34+ cells at the onset of blast crisis. In the second and third samples the percentage of CD34+ DR+ blast cells decreased slightly and up to 32% of cells in the third sample expressed the CD19 antigen. Optimal proliferation of cells derived from the first sample required the presence of exogenous sCD23 and to a lesser extent IL7. The stimulatory effects of sCD23 and IL7 were clearly reduced 4 months later and no longer detected after 6 months. This variability in growth factor response along with disease progression may be related to phenotypic differentiation. There was no evidence for lymphoid or myeloid maturation after 4 days of liquid culture. Our results in conjunction with previous studies are in agreement with sCD23-involvement in the complex control of proliferative processes at both normal and leukemic stages, demonstrating that cytokines are critical in determining CML cell proliferation.
authors.affiliation: URA CNRS 1172, CHRU La Milétrie, Poitiers, France.
authors.forename: F
authors.initials: F
authors.lastname: Morel
authors.forename: V
authors.initials: V
authors.lastname: Delwail
authors.forename: A
authors.initials: A
authors.lastname: Brizard
authors.forename: A
authors.initials: A
authors.lastname: Meseri
authors.forename: F
authors.initials: F
authors.lastname: Guilhot
authors.forename: P G
authors.initials: PG
authors.lastname: de LaForest
authors.forename: J C
authors.initials: JC
authors.lastname: Lecron
mesh_terms: D000210:Acute-Phase Reaction; D001752:Blast Crisis / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects; D005260:Female; D005434:Flow Cytometry; D016298:Hematopoietic Cell Growth Factors / Q000494:pharmacology; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology; D007377:Interleukin-3 / Q000494:pharmacology; D015851:Interleukin-7 / Q000494:pharmacology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D008875:Middle Aged; D010641:Phenotype; D017455:Receptors, IgE / Q000502:physiology*; D019089:Stem Cell Factor; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013997:Time Factors; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000473:pathology
chemical_list: D016298:Hematopoietic Cell Growth Factors; D007375:Interleukin-1; D007377:Interleukin-3; D015851:Interleukin-7; D017455:Receptors, IgE; D019089:Stem Cell Factor; D013755:Tetradecanoylphorbol Acetate